Given the disappointing outcomes of Bcl-2 inhibitor ABT-199 monotherapy in chronic lymphocytic leukemia, the combination of triptolide with ABT-199 has emerged as a promising strategy for acute myeloid leukemia treatment, as it enhances cytotoxicity by effectively targeting antiapoptotic proteins (Bcl-2 and Mcl-1), which may help improve therapeutic efficacy [1015]. The gene discussed is BCL2; the disease is acute myeloid leukemia.